Objective To compare the efficacy and safety of clozapine combined with risperidone in the treatment of refractory schizophrenia. Methods 63 cases were divided into two groups randomly,32 cases of treatment-refractory schizophrenia were treated with risperidone combined clozapine( the treatment group ) and 31 cases were treated with risperidone( the control group ). The clinical effect of patients were measured with positive and negative symptoms scale( PANSS ), and side effects were assessed with treatment emergent symptoms scale( TESS )respectively before and after 4,8,12 week treatment. Results There were significant differences in the curative effect between the two groups( P <0.05 ). After eight weeks treatment, total score of PANSS in two groups were much lower than before,the treatment group had greater decreases. After twelve weeks treatment,total score of PANSS in the treatment group was lower than that in the control group. There were statistical differences between the two groups( P <0. 05 ). Conclusion Clozapine combined with risperidone has curative effect affirmation to treat TRS,this deserves utilization in the clinical area.%目的 探讨利培酮联合氯氮平治疗难治性精神分裂症(TRS)的疗效及安全性.方法 将63例TRS患者随机分为利培酮合并氯氮平组(治疗组)32例和利培酮组(对照组)31例,两组治疗后4、8、12周均以阳性与阴性症状量表(PANSS)评定疗效,治疗意外症状量表(TESS)评定不良反应.结果 治疗组和对照组治疗TRS的疗效比较差异有统计学意义(P＜0.05).治疗后8周,两组PANSS总分均较治疗前下降,治疗组下降更明显.两组治疗12周后PANSS总分比较,治疗组明显低于对照组,差异有统计学意义(P＜0.05).结论 利培酮联合氯氮平治疗TRS的疗效肯定,值得临床应用.
展开▼
